Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line antimalarials in Nigeria.

Akintunde Sowunmi | Godwin Ntadom | Kazeem Akano | Folasade O Ibironke | Adejumoke I Ayede | Chimere Agomo | Onikepe A Folarin | Grace O Gbotosho | Christian Happi | Stephen Oguche | Henrietta U Okafor | Martin Meremikwu | Philip Agomo | William Ogala | Ismaila Watila | Olugbenga Mokuolu | Finomo Finomo | Joy C Ebenebe | Nma Jiya | Jose Ambe | Robinson Wammanda | George Emechebe | Wellington Oyibo | Francis Useh | Temitope Aderoyeje | Titilope M Dokunmu | Omobolaji T Alebiosu | Sikiru Amoo | Oluwabunmi K Basorun | Olubunmi A Wewe | Chukwuebuka Okafor | Odafe Akpoborie | Bayo Fatunmbi | Elsie O Adewoye | Nnenna M Ezeigwe | Ayoade Oduola
Infectious diseases of poverty | 2019

The development and spread of artemisinin-resistant Plasmodium falciparum malaria in Greater Mekong Subregion has created impetus for continuing global monitoring of efficacy of artemisinin-based combination therapies (ACTs). This post analyses is aimed to evaluate changes in early treatment response markers 10 years after the adoption of ACTs as first-line treatments of uncomplicated falciparum malaria in Nigeria.

Pubmed ID: 31383040

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: World Health Organization, International
    Id: 001

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


New England Biolabs (tool)

RRID:SCR_013517

An Antibody supplier

View all literature mentions